128: The Relaxback UK Show with Mike Dilke - Episode 128

128: The Relaxback UK Show with Mike Dilke - Episode 128

In the latest episode of the Relaxback UK Show, hosted by Mike Dilke, listeners are treated to a captivating discussion on two diverse topics: groundbreaking developments in leukemia treatment and the intricacies of breakfast choices. The episode kicks off with an in-depth conversation with Dr. Juho Jalkanen, CEO of Farron Pharmaceuticals, who shares promising results from phase two trials of a new drug, Bexmarilimum, designed to tackle a rare and deadly form of leukemia.

The drug has shown remarkable efficacy, increasing survival rates from 5.6 months to 13.4 months, and demonstrating a response rate of over 60% among patients. Dr. Jalkanen emphasizes the significance of this breakthrough, which is the culmination of twenty years of meticulous research and development, involving leading research sites across the US, UK, and Finland. The conversation shifts gears as Mike Dilke welcomes Dr.

Neil Buttery, a food author and podcaster, and Rosie Hook, Senior Brand Manager at Lizzy's, to explore the fascinating world of breakfast choices. The discussion delves into the factors influencing breakfast decisions, revealing health improvement desires as a major driving force behind choices. The survey conducted by Lizzy’s highlights trends like low sugar and high protein preferences, showcasing the evolving landscape of nutrition.

The episode emphasizes the complexity of dietetics and the constant evolution of dietary advice, inviting listeners to explore the Great British Breakfast Report for more insights. As the episode concludes, Mike Dilke reminds listeners of the importance of maintaining good posture and introduces Relaxback UK’s innovative solutions, encouraging those with back concerns to visit relaxbackuk.com. He invites the audience to join him next week for more intriguing interviews and discussions.